Bottom line
Is RAGHX a good fund? The bottom line
RAGHX is a share class of Virtus KAR Health Sciences Fund, an actively managed health care sector mutual fund from Virtus.
Annual fees run 1.41% — about $141 a year on every $10,000 invested, more expensive than 78% of health care sector funds we track.
It returned +1.3% over one year, +2.4% a year over five years, +6.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $91.7 million in net assets and 24 holdings, its largest position is Eli Lilly & Company (14.8%) and the top 10 make up 57.6% of the portfolio.
This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.
What to watch
- Expensive for its category (1.41%)
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 57.6% of assets
- Front-end sales load up to 5.5%
- 12b-1 marketing fee of 0.25% a year
Updated Nov 19, 2026
What RAGHX invests in
The fund seeks long-term capital appreciation .
The fund pursues long-term capital appreciation in health sciences-related companies. The fund invests in a select group of health science-related companies believed by the funds subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. Under normal circumstances, the fund invests at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. As of the date of this prospectus, the fund considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. Although the fund may invest in companies of any market capitalization, the fund does not currently intend to invest more than 15% of its assets in…
From the fund's prospectus (filed Oct 22, 2026).
RAGHX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| RAGHX | +1.3% | +2.4% | +6.2% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What RAGHX costs
On a $10,000 investment, RAGHX's 1.41% expense ratio costs about $141 a year. The prospectus estimates $2,148 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
RAGHX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Company LLY | 14.84% |
| 2 | West Pharmaceutical Services Inc WST | 5.92% |
| 3 | Abbvie Inc ABBV | 5.52% |
| 4 | Vertex Pharmaceuticals Inc VRTX | 5.32% |
| 5 | Merck & Company Inc MRK | 5.06% |
| 6 | Unitedhealth Group Inc UNH | 4.65% |
| 7 | Mckesson Corp MCK | 4.57% |
| 8 | Mettler-toledo International Inc MTD | 3.99% |
| 9 | Intuitive Surgical Inc ISRG | 3.89% |
| 10 | Amgen Inc AMGN | 3.85% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 57.6% of the fund. See all top 25 holdings and asset mix →